Stockscreener 앱 받기
243.82
1.25%
-3.09
전일 마감가:
$246.91
열려 있는:
$245.65
하루 거래량:
636.25K
Relative Volume:
0.68
시가총액:
$15.32B
수익:
$4.44B
순이익/손실:
$29.49M
주가수익비율:
-13,251.09
EPS:
-0.0184
순현금흐름:
$1.19B
1주 성능:
+0.14%
1개월 성능:
+6.18%
6개월 성능:
+51.32%
1년 성능:
+116.77%
1일 변동 폭
$238.42
$247.26
1주일 범위
$238.42
$250.49
52주 변동 폭
$105.00
$250.49
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
명칭
Jazz Pharmaceuticals Plc
전화
353-1-634-7800
주소
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
243.82 | 15.32B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 재개 | Raymond James | Outperform |
| 2026-02-27 | 개시 | Barclays | Overweight |
| 2025-11-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-15 | 개시 | Deutsche Bank | Buy |
| 2025-03-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-26 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Buy |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-11-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-09-29 | 개시 | Raymond James | Mkt Perform |
| 2023-06-12 | 재개 | Wells Fargo | Equal Weight |
| 2022-12-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-11-19 | 재개 | Goldman | Buy |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-10-05 | 개시 | Citigroup | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-05-19 | 재개 | JP Morgan | Overweight |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | 개시 | Jefferies | Buy |
| 2020-03-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Neutral |
| 2019-08-21 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Peer Perform |
| 2018-11-08 | 재확인 | B. Riley FBR | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | 재확인 | H.C. Wainwright | Neutral |
| 2018-03-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
symbol__ Stock Quote Price and Forecast - CNN
JAZZ Maintained by Deutsche Bank -- Price Target Raised to $270 - GuruFocus
Jazz Patent Suit Over Xyrem Survives Dismissal In NJ - Law360
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals (JAZZ) Q4 2024 earnings summary - Quartr
JAZZ Maintains Rating by Truist Securities -- Price Target Lowered to $254 - GuruFocus
Sleep Apnea Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com
Jazz Pharmaceuticals (JAZZ) director Cozadd sells 6,000 shares via 10b5-1 trade - Stock Titan
Jazz Pharmaceuticals Holds Steady Near Resistance as Volume Patterns Signal CautionQuality Factor - dars.gov.et
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Growth Potential with a Strategic Focus in Biotechnology - DirectorsTalk Interviews
Jazz Pharmaceuticals PLC at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
JAZZJazz Pharmaceuticals plc Options - Finviz
Jazz Pharmaceuticals (JAZZ) Breakout Keeps Valuation In Focus Following Zepzelca Setback And Ziihera Hopes - simplywall.st
Jazz Pharmaceuticals (JAZZ) EVP reports RSU tax withholding and retains 47,911 shares - Stock Titan
Jazz Pharmaceuticals (JAZZ) CEO shares withheld to cover RSU tax obligations - Stock Titan
Jazz Pharmaceuticals (JAZZ) EVP Iannone reports RSU tax-withholding share disposition - Stock Titan
Jazz Pharmaceuticals (JAZZ) insider RSU tax withholding detailed - Stock Titan
Jazz Pharmaceuticals (JAZZ) CFO reports 3,343-share tax withholding - Stock Titan
Jazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs? - FXEmpire
Jazz Pharmaceuticals stock hits all-time high at 243.39 USD - Investing.com
Jazz Pharmaceuticals stock hits all-time high at 243.39 USD By Investing.com - Investing.com Nigeria
Form 144 Jazz Pharmaceuticals Plc For: 1 July By Investing.com - Investing.com Nigeria
Bruce Cozadd files Form 144 to sell shares — Jazz Pharmaceuticals (NASDAQ: JAZZ) - Stock Titan
Enterprise value to revenue forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView
Price to earnings forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView
Price to book forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView
Is Jazz Pharmaceuticals (JAZZ) Using AbCellera Deal to Quietly Redefine Its Oncology Strategy? - simplywall.st
3 Overrated Stocks Walking a Fine Line - Yahoo Finance UK
Price to sales forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? - TradingView
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks - AOL.com
Jazz Pharmaceuticals (JAZZ) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary - Quartr
Jazz Pharmaceuticals (JAZZ) Q1 2026 earnings summary - Quartr
Erica Jefferson Joins Jazz Pharmaceuticals as Chief Communications Officer - hrtoday.in
JAZZ Forecast — Price Target — Prediction for 2027 - TradingView
Jazz Pharmaceuticals' lung cancer drug setback in late-stage trials: Here's why the stock impact may be more limited than it looks - MSN
Jazz Pharma announces late-stage trial setback for lung cancer therapy - MSN
Jazz Pharmaceuticals Public Limited Company Actuals & Estimates (NASDAQ:JAZZ) - TradingView
Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade) (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals (JAZZ) Reframed Zepzelca Growth, Is The Stock Still Below Fair Value? - simplywall.st
Strong Leaders Build Strong Teamsand Strong Teams Change Patients’ LivesJazz Pharmaceuticals - Oncodaily
Jazz Pharmaceuticals PLC (HAM:J7Z) Stock Price, Trades & News - GuruFocus
Jazz Pharmaceuticals (JAZZ) Stock Gets Fair Value Boost As Ziihera Views Split Analysts - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Expands AbCellera Tie Up As Zepzelca Trial Misses Goal - Yahoo Finance
Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce Collaboration - Yahoo Finance UK
Will Zepzelca’s Failed LAGOON Trial in Second-Line SCLC Change Jazz Pharmaceuticals' (JAZZ) Narrative? - simplywall.st
JAZZ’s Zepzelca fails to meet primary goal in lung cancer study - MSN
Investor Outlook: Jazz Pharmaceuticals Plc (JAZZ) And Its 14.40% Potential Upside - DirectorsTalk Interviews
Jazz Pharmaceuticals PLC (JAZZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jazz Pharmaceuticals (JAZZ) Stock Could Be 73% Below Fair Value After Recent Pullback - simplywall.st
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies - Yahoo Finance
Jazz Pharmaceuticals Plc (JAZZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):